Loading
A phase 1/2 trial of Alcestobart run by BeiGene, completed.
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03744468 by BeiGene, with 147 participants enrolled, started 2018-11-13. Conditions recorded: Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion and NSCLC for Phase 2 Dose Expansion. Interventions recorded: Surzebiclimab, Tislelizumab and Alcestobart.
Shares Alcestobart, Nanjing Leads Biolabs, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs, Non-small-cell lung cancer and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/